Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
13 févr. 2025 08h30 HE
|
Biodexa Pharmaceuticals PLC
February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
10 févr. 2025 08h30 HE
|
Biodexa Pharmaceuticals PLC
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or...
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
22 janv. 2025 08h30 HE
|
Biodexa Pharmaceuticals PLC
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...
Result of General Meeting
22 nov. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage...
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
12 nov. 2024 08h48 HE
|
Biodexa Pharmaceuticals PLC
November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage...
Notice of General Meeting
07 nov. 2024 16h30 HE
|
Biodexa Pharmaceuticals PLC
November 7, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing...
Biodexa Announces Successful Appeal of Nasdaq Delisting
15 oct. 2024 16h15 HE
|
Biodexa Pharmaceuticals PLC
Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
04 oct. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...
Interim results for the six months ended June 30, 2024
26 sept. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an...
ADR Ratio Change
19 sept. 2024 16h30 HE
|
Biodexa Pharmaceuticals PLC
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical...